Association Between Enfortumab Vedotin-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Akimasa Sanagawa, Hideo Kato, Takahiro Inoue et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the relationship between enfortumab vedotin (EV)-related adverse events and clinical outcomes in advanced urothelial carcinoma. Among 12 included studies, cutaneous toxicity was associated with improved overall survival (OS) and progression-free survival (PFS), although the association was less robust when adjusted for immortal time bias. Peripheral neuropathy also showed improved OS.
Key findings
- Cutaneous toxicity was associated with improved overall survival (OS) but less robust in ITB-adjusted analyses.
- Cutaneous toxicity correlated with improved progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR).
- Peripheral neuropathy showed improved OS across four studies, but PFS was not significantly associated.
Why it matters
Understanding the relationship between adverse events and clinical outcomes can help clinicians better assess the risks and benefits of enfortumab vedotin in treating advanced urothelial carcinoma, guiding patient management and treatment decisions.
What to keep in mind
The findings are limited by the retrospective nature of the included studies, a small number of studies, and residual heterogeneity in toxicity definitions.